Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase

Documenti analoghi

• Engineering of a Chimeric RB69 DNA Polymerase Sensitive to Drugs Targeting the Cytomegalovirus Enzyme
  di: Tchesnokov, Egor P., et al.
  Pubblicazione: (2009)
• Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Mutation in Reverse Transcriptase
  di: Tchesnokov, Egor P., et al.
  Pubblicazione: (2009)
• Mutations M184V and Y115F in HIV-1 Reverse Transcriptase Discriminate against “Nucleotide-competing Reverse Transcriptase Inhibitors”
  di: Ehteshami, Maryam, et al.
  Pubblicazione: (2008)
• Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and -independent Mechanisms
  di: Ehteshami, Maryam, et al.
  Pubblicazione: (2008)
• The M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Impairs Rescue of Chain-Terminated DNA Synthesis
  di: Götte, Matthias, et al.
  Pubblicazione: (2000)